Long-term efficacy of endoscopic coagulation for different types of gastric vascular ectasia

Table 1 Demographic and clinical features of the patients with gastrointestinal bleeding caused by gastric vascular ectasia

	Total	Groups2		P value
		LVE	EVE
No. of patients	38	14	24
Sex: male/female1	21 / 17	9/5	12/12	NS
Age, yr (medium)	69	67.5	72	NS
Bleeding from lesions at examination1	21	6	15	NS
Cauterization3
Method : HPC/APC1	13 / 25	6/8	7/17	NS
No. of treatment sessions (mean ± SD)	2.3 ± 1.6	1.1 ± 0.3	3.0 ± 1.6	< 0.0001
Observation period, mo (medium)	32	68.5	29.5	< 0.01
Medication during observation1
Proton pump inhibitors	15	4	11	NS
H2-receptor antagonists	20	9	11
None	3	1	2
Underlying diseases1
Chronic renal failure	15	3	12	NS
Liver cirrhosis	20	5	15	NS

¹Number of the patients;

²Localized vascular ectasia (LVE) denotes localized vascular ectasia and extensive vascular ectasia (EVE) denotes extensive vascular ectasia;

³Heater probe coagulation (HPC) denotes heater probe coagulation and argon plasma coagulation (APC) denotes argon plasma coagulation. NS: Not significant.

Table 2 Long-term efficacies of endoscopic cauterization therapies in the patients with gastrointestinal bleeding caused by gastric vascular ectasia n (%)

Groups	Recurrence rate	Re-bleeding rate
LVE	1 (7.1)	1 (7.1)
Without CRF	0 (0.0)	0 (0.0)
With CRF	1 (33.3)	1 (33.3)
EVE	24 (100.0)	14 (58.3)
Without CRF	12 (100.0)	6 (50.0)
With CRF	12 (100.0)	8 (66.7)

LVE: Localized vascular ectasia, EVE: Extensive vascular ectasia; CRF: Chronic renal failure.